Neoadjuvant Vibostolimab Plus Pembrolizumab Demonstrates Act

Neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage IIIB-D melanoma.

Related Keywords

Zurich , Züsz , Switzerland , Reinhard Dummer , University Hospital Zurich ,